Get Full Government Meeting Transcripts, Videos, & Alerts Forever!
Get email alerts on the Medical Research topic
No spam. Unsubscribe anytime.
Committee approves AB 1103 to speed state review of federally approved controlled‑substance clinical research
Summary
AB 1103 would create an expedited state review process for federally sanctioned clinical research involving Schedule I and II controlled substances by updating the Research Advisory Panel of California (RAP C) procedures. Sponsors said the change would prevent long delays that have halted studies; witnesses included veterans who sought treatment.
Assembly Bill 1103: The Senate Committee on Health considered AB 1103, which would create an expedited state review and approval pathway for federally authorized drug trials and clinical research involving Schedule I and II controlled substances through the Research Advisory Panel of California (RAP C), housed in the Department of Justice.
Why it matters: Supporters said the current RAP C process can delay research start dates—sometimes halting studies for months—because panel action historically required majority votes at regularly scheduled bimonthly meetings. Witnesses described urgent clinical research needs for therapies potentially aiding people with treatment‑resistant conditions, including veterans with post‑traumatic stress disorder or substance‑use disorders. The sponsor said the panel’s statutes had not kept pace with modern research and that prior statutory language caused RAP C to stop meeting for nearly a year, halting almost 100 studies.
Testimony: Khashid Khoja, director of public policy for VETS (the sponsor), summarized outreach with RAP C leadership and stakeholders and said AB 1103 represents about two years of work with researchers and panel members. A veteran who testified described traveling outside the U.S. for ibogaine treatment and urged quicker state review so research and potential treatments can be evaluated in California. Multiple medical, research and advocacy organizations registered support and the committee record shows no formal opposition.
Committee action and status: The committee accepted author amendments and passed AB 1103 as amended, referring it to the Senate Judiciary Committee. The hearing record indicates the measure passed committee with recorded votes showing a final vote count of 11 ayes, 0 noes.
Next steps: AB 1103 will be referred to the Senate Judiciary Committee for further action; sponsors said they will continue coordination with RAP C and research stakeholders.
